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Toll-like receptors (TLRs) are pattern recognition receptors playing a fundamental role in
sensing microbial invasion and initiating innate and adaptive immune responses. TLRs
are also triggered by danger signals released by injured or stressed cells during sepsis.
Here we focus on studies developing TLR agonists and antagonists for the treatment of
infectious diseases and sepsis. Positioned at the cell surface, TLR4 is essential for sens-
ing lipopolysaccharide of Gram-negative bacteria, TLR2 is involved in the recognition of a
large panel of microbial ligands, while TLR5 recognizes flagellin. Endosomal TLR3, TLR7,
TLR8, TLR9 are specialized in the sensing of nucleic acids produced notably during viral
infections.TLR4 andTLR2 are favorite targets for developing anti-sepsis drugs, and antago-
nistic compounds have shown efficient protection from septic shock in pre-clinical models.
Results from clinical trials evaluating anti-TLR4 and anti-TLR2 approaches are presented,
discussing the challenges of study design in sepsis and future exploitation of these agents
in infectious diseases.We also report results from studies suggesting that theTLR5 agonist
flagellin may protect from infections of the gastrointestinal tract and that agonists of endo-
somalTLRs are very promising for treating chronic viral infections. Altogether, TLR-targeted
therapies have a strong potential for prevention and intervention in infectious diseases,
notably sepsis.
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INTRODUCTION
Sepsis is one of the leading causes of death worldwide. Incidence
of severe sepsis is increasing and mortality rates remain signifi-
cantly high despite early care management (1). Moreover, more
than 30% of survivors develop long-term functional disabilities
and cognitive impairments (2). The Surviving Sepsis Campaign is
a global initiative incepted in early 2000s with the aim to improve
sepsis diagnosis and treatment in order to enhance the awareness
of sequelae and to decrease high mortality rates associated with
sepsis1. In collaboration with many countries in Europe and the
United States, the Surviving Sepsis Campaign suggests evidence-
based guidelines and bundles. The most recent guidelines rec-
ommend acute resuscitation of septic patients, administration of
antibiotics and support of organ failure. Yet, no treatment tar-
geting the underlying mechanism of sepsis is actually available
(3). Recombinant human activated protein C (rhAPC, Xigris®, Eli
Lilly), the only drug specifically registered for sepsis, has recently
been withdrawn from the market following the negative results
from the PROWESS-SHOCK study that did not show reduction
in mortality at 28 or 90 days in patients with septic shock (4).
It is generally admitted that sepsis results from a dysregulated
host response to an initial insult, characterized by inflamma-
tion mediating tissue damage and organ failure and an immune
1http://www.survivingsepsis.org
suppression state responsible for the development of secondary
infections (5–7). The immune response to an infection is initi-
ated by the sensing of microbial structures through families of
receptors collectively called pattern recognition receptors (PRRs).
The most well-described families comprise Toll-like receptors
(TLRs),nucleotide binding oligomerization domains (NODs)-like
receptors (NLRs), c-type lectin receptors (CLRs, such as dectin-
1, dectin-2, DC-SIGN), RIG-I-like receptors (RLRs, RIG-I, and
MDA5), and intra-cytosolic DNA sensors. PRRs are expressed by
innate immune cells like dendritic cells and macrophages. The
binding of microbial ligands to PRRs promotes the release of medi-
ators, among which cytokines, that initiate and regulate the inflam-
matory response necessary to eliminate invasive pathogens and
coordinate the development of the adaptive immune response (8,
9). Innate immune cells are also triggered by damage (or danger)-
associated molecular patterns (DAMPs), known as alarmins.
DAMPs are endogenous components commonly released by
injured or stressed cells, such as nucleic acids, histones, uric
acid crystals, ATP, cytochrome c, S100 molecules, and HMGB1.
DAMPs are primarily sensed through the NLRP3 inflammasome,
which controls the secretion of IL-1β and IL-18 (10).
The concept of PRRs sensing microbial-associated molecu-
lar patterns (MAMPs) and discriminating self from non-self
molecular structures was proposed by Janeway (11). Two major
cornerstone discoveries largely confirmed Janeway’s concept. The
first one was the demonstration of the essential antifungal role of
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the Toll protein in Drosophila (12). The second one arose from
the positional cloning linking LPS (commonly called endotoxin)
unresponsive phenotype of C3H/HeJ and C57BL/10ScCr strains
of mice to missense and null mutations of the Toll-like receptor 4
(Tlr4) gene (13). The importance of these discoveries and of the
role of dendritic cells as central regulators of innate and adap-
tive immunity has been acknowledged by the 2011 Nobel Prize in
Physiology or Medicine attributed to Bruce A. Beutler and Jules
A. Hoffmann “for their discoveries concerning the activation of
innate immunity” and to Ralph M. Steinman “for his discovery of
the dendritic cell and its role in adaptive immunity” (14).
TOLL-LIKE RECEPTORS
Toll-like receptors belong to the most studied family of PRRs,
due to their central role in host defenses and involvement in a
number of pathological processes that include sepsis. TLRs are
type I trans-membrane proteins composed of an extracellular
leucine-rich repeat (LRR) domain involved in ligand recogni-
tion, a trans-membrane domain, and a Toll-interleukin 1 receptor
(TIR) domain involved in signaling (9, 15). About 10 functional
human TLRs (TLR1-10) and 12 functional mouse TLRs (TLR1-9,
TLR11-13) have been described, each one being involved in the
sensing of distinct microbial products (Table 1). Expressed at the
cell surface, TLR4 detects LPS from Gram-negative bacteria. TLR4
shuttles to late endosome to induce alternative signaling follow-
ing LPS sensing. TLR2 as heterodimers in association with either
TLR1 or TLR6 (and possibly TLR10) senses a variety of micro-
bial products, such as lipopeptides, lipoproteins, peptidoglycan,
porins, β-glucan, glycosylphosphatidylinositol (GPI) anchors, and
glycoproteins from Gram-positive bacteria, Gram-negative bacte-
ria, mycoplasma, mycobacteria, fungi, parasites, and viruses. TLR5
senses flagellin of bacterial flagella. TLR3, TLR7, TLR8, and TLR9
are strategically expressed in endosomal compartments to rec-
ognize microbial nucleic acids: double-stranded RNA (dsRNA)
by TLR3, single-stranded RNA (ssRNA) by TLR7 and TLR8, and
unmethylated CpG motif containing DNA by TLR9 (Table 1). It is
therefore not surprising that endosomal TLRs have been primar-
ily involved in host defenses against viruses, whereas TLR1, TLR2,
and TLR4-6 have been mainly involved in host response to bac-
terial and fungal infection. TLRs cooperate with other molecules
to recognize microbial ligands. For example, TLR2 requires CD14,
CD36, and dectin-1 for the recognition of peptidoglycan, lipopep-
tides, and β-glucan, respectively. Of note, TLRs are also triggered
by DAMPs released by injured or stressed cells during infection
(16) (Table 1). TLR activation enables pathogen elimination by
promoting bactericidal activity of leukocytes, and maturation
and function of antigen presenting cells, thus orchestrating the
development of adaptive immune responses (17).
The signaling pathways resulting from TLR triggering engage
adaptors that are recruited by TIR/TIR domain interactions
(Table 1): myeloid differentiation primary response gene (18)
(MyD88), TIR domain-containing adaptor protein (TIRAP, also
known as MAL), TIR domain-containing adaptor inducing
interferon (IFN)β (TRIF), and TRIF related adaptor molecule
(TRAM) (19). MyD88 is essential for signaling through all TLRs
except TLR3 and is involved in early nuclear factor-κB (NF-
κB) and mitogen-activated protein kinases (MAPKs) activation
and pro-inflammatory gene expression. TIRAP serves as a bridge
to recruit MyD88 to TLR2 and TLR4. TRIF initiates MyD88-
independent IFN regulatory factor 3 (IRF3) and late NF-κB activa-
tion involved in the production of type I IFNs and IFN-inducible
genes (19, 20). TRIF is recruited to the cytoplasmic domain of
TLR3 and, in late endosome, through TRAM that bridges TRIF
to TLR4. A fifth TIR domain-containing adaptor, sterile α-, and
armadillo-motif containing protein (SARM) acts as a negative reg-
ulator of TLR3 and TLR4 signaling. SARM interacts with TRIF and
inhibits the induction TRIF-dependent genes.
The signaling pathways activated downstream TLRs have some
redundancy. Yet, the engagement of multiple TLRs, especially
MyD88 and TRIF-dependent TLRs, have synergistic effects on
host responses (21, 22). Intracellular cross talk between signal-
ing pathways may also occur when different families of PRRs are
involved. For example, dectin-1 synergizes with TLR2 and TLR4
and increases cytokine production through canonical and non-
canonical NF-κB pathways (23, 24). Moreover, a single MAMP
can be detected by different PRRs. This differential sensing is
primarily depending on the localization of the MAMP. Indeed,
flagellin is sensed by TLR5 expressed at the cell surface and by
the NAIP5/NLRC4 (also known as IPAF) inflammasome when
localized in the cytoplasm (25–27). Similarly, peptidoglycans
stimulate membrane TLR2 and intra-cytosolic NOD1/NOD2-
dependent cell activation (28). Interestingly, some CpG and non-
CpG oligodeoxynucleotides directly stimulate and polarize T-cells
through TLR9 and MyD88-independent mechanisms (29), possi-
bly through intracellular DNA sensors. Recently, Hagan et al. and
Kayagaki et al. demonstrated non-canonical TLR4-independent
recognition of intracellular LPS through an uncharacterized recep-
tor (30, 31). This unconventional mode of LPS sensing activates
caspase-11-dependent IL-1β secretion and sensitizes mice to endo-
toxic shock. All these observations indicate that the host has
evolved different strategies to sense invading microorganisms.
Ideally, all possible interactions should be characterized and/or
anticipated, so that the effect of treatment application can be pre-
dicted and/or translated. This mandates carefully planned experi-
ments that represent real-life conditions and a detailed knowledge
of compound’s mode of action. Obviously, the redundancy of
microbial sensing pathways should be taken into consideration
when developing or applying targeted-treatment strategies to a
single PRR.
Experimental animal models and human clinical studies sup-
port a crucial role for TLRs in infectious diseases. The first evidence
came from the observation that TLR4 defective C3H/HeJ and
C57BL/10ScCr mice are hyporesponsive to LPS and susceptible
to otherwise non-lethal infection with Escherichia coli and Sal-
monella typhimurium. Subsequent studies with mice knockout in
TLRs or TLR adaptor molecules have demonstrated the impor-
tance of the TLR pathway in host defenses. For example, TLR2
knockout mice are highly susceptible to infections by Staphylo-
coccus aureus and Streptococcus pneumoniae (32). More recently,
human association studies have linked polymorphisms affecting
TLR expression or TLR structure with an augmented propensity
to develop infections (32–35).
The discovery of TLRs and their involvement in innate immune
responses has attracted much interest into the development
of drugs for controlling infections and improving sepsis
management. This field of research has been very dynamic, and
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Table 1 |Toll-like receptors and their ligands.
Receptor Sub-cellular expression Adaptor molecule Ligand Origin
TLR1 (with TLR2) Cell membrane MyD88/TIRAP Triacyl lipopeptides Bacteria, mycobacteria
Soluble factors Neisseria meningitidis
TLR2 (with TLR1 or TLR6) Cell membrane MyD88/TIRAP Lipoproteins, lipopeptides Various pathogens
Lipoteichoic acid Gram-positive bacteria
Peptidoglycan Bacteria
Lipoarabinomannan Mycobacteria
Phenol-soluble modulin,
porins
Staphylococcus epidermidis,
Neisseria
Atypical LPS Leptospira interrogans,
Porphyromonas gingivalis
Glycoinositolphospholipids,
glycolipids
Trypanozoma,Toxoplasma,
Plasmodium
Beta-glucan, mannan Fungi
Core and NS3 proteins,
dUTPase, glycoproteins
Hepatitis virus, Epstein–Barr virus,
Cytomegalovirus
HSP70 Host
TLR3 Endolysosomal TRIF Double-stranded RNA Viruses
TLR4 Cell membrane and
endolysosomal
MyD88/TIRAP,
TRIF/TRAM
LPS Gram-negative bacteria
O-linked mannan Fungi
Taxol Plants
Fusion and envelope protein Respiratory syncytial virus, mouse
mammary tumor virus
HSP60 Chlamydia pneumoniae
HMGB1, HSP70, fibronectin,
fibrinogen
Host
TLR5 Cell membrane MyD88 Flagellin Flagellated bacteria
TLR6 (with TLR2) Cell membrane MyD88/TIRAP Diacyl lipopeptides,
lipoteichoic acid, β-glucan
Mycoplasma, Gram-positive
bacteria, fungi
TLR7 Endolysosomal MyD88 Single-stranded RNA Viruses, bacteria
Imidazoquinoline, loxoribine,
bropirimine
Synthetic compounds
TLR8 Endolysosomal MyD88 Single-stranded RNA Viruses, bacteria
Imidazoquinoline Synthetic compounds
TLR9 Endolysosomal MyD88 CpG-containing DNA Bacteria, viruses, fungi
Homozoin Plasmodium falciparum
TLR10 (±TLR1 or TLR2) Cell membrane MyD88 Lipopeptides (prediction)
TLR11 Endolysosomal MyD88 Flagellin Flagellated bacteria
TLR12 Endolysosomal MyD88 Profilin Apicomplexan parasites
TLR13 Endolysosomal MyD88 23S RNA Bacteria
numerous compounds focused on TLRs have been tested in ani-
mals and human subjects. TLR agonists are powerful adjuvant
constituting the heart of vaccine efficacy enhancement. Moreover,
they are promising TLR-directed agents developed for autoim-
mune diseases and cancer (36). These two particular aspects of the
TLR-targeting field will not be addressed in this review. Herein, we
will review the most popular agonist (TLR3, TLR5, TLR7, TLR8,
TLR9) and antagonist (TLR2, TLR3, TLR4, TLR9) agents used in
pre-clinical and clinical models of acute and chronic infections,
including sepsis. Relevant registered clinical trials2 are listed in
Table 2.
2www.clinicaltrials.gov
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Table 2 | Selection of clinical trials testing drugs targetingTLRs for bacterial and viral infections.
Compound Company/organism Target Effect Clinical phase Clinical trial no. Aim Comment
E5564
(eritoran)
Eisai Inc TLR4 Antagonist Randomized,
double-blind phase 2
NCT00046072 Safety and efficacy in
patients with severe sepsis
(37)
E5564 Eisai Inc TLR4 Antagonist Randomized,
double-blind phase 3
NCT00334828 Treatment and reduced
mortality of severe sepsis
(38)
TAK-242
(Resatorvid)
Takeda TLR4 Antagonist Randomized,
double-blind phase 3
NCT00143611 Efficacy and safety in
patients with severe sepsis
(39)
TAK-242 Takeda TLR4 Antagonist Randomized,
double-blind phase 3
NCT00633477 Efficacy and safety in
patients with sepsis-induced
cardiovascular and
respiratory failure
Study
terminated
NI-0101 NovImmune SA TLR4 Antagonist Randomized,
double-blind phase 1
NCT01808469 Safety and PK/PD* in
healthy volunteers
Currently
recruiting
Poly-ICLC
(Hiltonol)
Rockefeller University TLR3 Agonist Randomized,
double-blind phase 1
NCT00646152 Safety and tolerability in
healthy volunteers
Active, not
recruiting
FluMist+
Poly(I:C12U)
Hemispherx
Biopharma
TLR3 Agonist Randomized,
double-blind phase 1
and phase 2
NCT01591473 Immunogenicity and safety
of human influenza vaccine
in healthy volunteers
Currently
recruiting
Poly(I:C12U) Hemispherx
Biopharma
TLR3 Agonist Randomized, open
label phase 2
NCT00035893 Effectiveness in increasing
the HAART-free time interval
before HIV rebound
No results
available
Poly(I:C12U) Hemispherx
Biopharma
TLR3 Agonist Randomized, open
label phase 2
NCT00035581 Safety and efficacy in
combination with HAART in
HIV subjects
Study
terminated
SD-101 Dynavax Technologies
Corporation
TLR9 Agonist Randomized, single
blind phase 1
NCT00599001 Safety and PK/PD in healthy
male volunteers
No results
available
SD-101 Dynavax Technologies
Corporation
TLR9 Agonist Randomized, single
blind phase 1
NCT00823862 Efficacy and PK/PD in
treatment-naïve genotype 1
HCV subjects
(40)
IMO-2125 Idera
Pharmaceuticals, Inc
TLR9 Agonist Randomized,
double-blind phase 1
NCT00728936 Dose escalation and PK/PD
in non-responders HCV
subjects
(41)
IMO-2125 Idera
Pharmaceuticals, Inc
TLR9 Agonist Randomized,
double-blind phase 1
NCT00990938 Dose escalation, safety, and
PK/PD in treatment-naïve
genotype 1 HCV subjects
(42)
CPG10101 Pfizer TLR9 Agonist Randomized, open
label phase 1
NCT00142103 Treatment of relapsed HCV
subjects
No results
available
CPG10101 Pfizer TLR9 Agonist Randomized, open
label phase 2
NCT00277238 Efficacy and PK/PD in
non-responders HCV
subjects
No results
available
Chloroquine Assistance Publique
Hôpitaux De Marseille
TLR9 and
TLR4
Unknown Randomized,
double-blind phase 3
NCT00391313 Efficacy and safety in
patients with Chikungunya
Study
terminated
Chloroquine National University
Hospital, Singapore
TLR9 and
TLR4
Unknown Randomized,
double-blind phase 2
NCT01078779 Prevention of influenza (43)
(Continued)
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Table 2 | Continued
Compound Company/organism Target Effect Clinical phase Clinical trial no. Aim Comment
Chloroquine University of Sao
Paulo
TLR9 and
TLR4
Unknown Randomized,
double-blind phase 1
and phase 2
NCT00849602 Treatment of patients with
dengue
(44)
Imiquimod
(Aldara)
Graceway
Pharmaceuticals, LCC
TLR7 Agonist Randomized,
double-blind phase 3
NCT00735462
NCT00674739
Treatment, safety, and
effectiveness in external
genital warts due to HPV
(45)
Resiquimod
(R-848)
Graceway
Pharmaceuticals, LCC
TLR7 and
TLR8
Agonist Non-randomized,
single blind phase 2
NCT00116662
NCT00116675
Safety and efficacy in
common warts in pediatric
subjects up to 4 and
12 weeks
No results
available
Resiquimod Graceway
Pharmaceuticals, LCC
TLR7 and
TLR8
Agonist Non-randomized,
single blind phase 2
NCT00114920
NCT00115141
NCT00117871
NCT00117923
Safety and efficacy in
common warts in adults up
to 4 and 12 weeks
No results
available
Imiquimod
(Aldara)
Medical University of
Vienna
TLR7 Agonist Non-randomized,
single blind phase 2
NCT00941811 Treatment of vulvar
intraepithelial neoplasias 2/3
(VIN) and ano-genital warts
Unknown
Miltefosine
and Imiquimod
Foundation Fader TLR7 Agonist Randomized,
double-blind phase 2
NCT01380314 Treatment of cutaneous
leishmaniasis
No results
available
Imiquimod MEDA Pharma GmbH
and Co. KG
TLR7 Agonist Randomized,
double-blind phase 4
NCT00189293 Recurrence rate after
treatment of external
ano-genital warts
No results
available
Imiquimod MEDA Pharma GmbH
and Co. KG
TLR7 Agonist Non-comparative,
open label phase 4
NCT00761371 Treatment of external genital
or perianal warts in HIV
subjects
(46)
Antimony and
Imiquinod
Drugs for Neglected
Diseases
TLR7 Agonist Randomized,
double-blind phase 3
NCT00257530 Treatment of cutaneous
leishmaniasis
(47)
Imiquimod Assistance
Publique-Hopitaux de
Paris
TLR7 Agonist Randomized, open
label phase 3
NCT01059110 Treatment of plantar warts Currently
recruiting
Imiquimod Conrad TLR7 Agonist Randomized, open
label phase 2
NCT01593124 Immune response of vaginal
tissue after exposure to
product
Active, not
recruiting
ANA 773 Hoffmann-La Roche TLR7 Agonist Randomized,
double-blind phase 1
NCT01211626 Safety and PK/PD in HCV
subjects and healthy
volunteers
(48, 49)
PF-04878691 Pfizer TLR7 Agonist Randomized,
double-blind phase 1
NCT00810758 Safety and PK/PD in healthy
volunteers
(50)
GS-9620 Gilead Sciences TLR7 Agonist Randomized,
double-blind phase 1
NCT01591668 Safety and PK/PD in
treatment-naïve HCV
subjects
Active, not
recruiting
GS-9620 Gilead Sciences TLR7 Agonist Randomized,
double-blind phase 1
NCT01590641
NCT01590654
Safety, PK/PD in HBV
virologically suppressed
subjects and in
treatment-naïve HBV
subjects
Currently
recruiting
*PK/PD: Pharmacokinetics/Pharmacodynamics.
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TOLL-LIKE RECEPTOR 4 ANTAGONISTS
LPS is the main pro-inflammatory molecule anchored in the out-
ermembrane of Gram-negative bacteria (51). Neutralization of
bacterial LPS, inhibition of its recognition by host cells or inhi-
bition of signaling downstream LPS binding to its receptor has
long been considered a promising approach for the treatment
of severe sepsis and septic shock. Interestingly, endotoxemia is
prevalent in septic patients, not only in those with Gram-negative
infection. Indeed, translocation of viable bacteria and LPS from
the gastrointestinal tract has been proposed to participate in the
pathophysiology of sepsis. TLR4 was identified 15 years ago as the
signal-transducing molecule of the LPS receptor complex (13),
which also comprises MD-2 and CD14. Thus, TLR4 is regarded
as a primary target for treating sepsis (52). TLR4 expression is
increased in human monocytes of healthy volunteers challenged
with LPS (53), as well as in patients with sepsis (54). Moreover,
polymorphisms in the TLR4 gene have been associated with Gram-
negative sepsis (33, 35). In the following sections, we present the
most advanced TLR4 antagonists developed for the treatment of
sepsis.
ERITORAN-E5564
Strategies to inhibit LPS-mediated toxic effects have been initiated
years before the discovery of TLR4 (13) and the unraveling of the
crystal structure of the TLR4-MD-2-LPS complex (55). Lipid A,
the toxic moiety of LPS, is highly conserved among endotoxins
and constitutes an ideal therapeutic target (56). E5531, developed
by Eisai Research Institute of Boston (Andover, MA, USA), was
the first-generation lipid A antagonist derived from Rhodobacter
capsulatus endotoxin. E5531 conferred protection in experimen-
tal models of endotoxemia and lethal infection with E. coli (57).
The protective effect likely occurred through the binding of E5531
to the TLR4-MD-2 complex and the inhibition of the interaction
between LPS and TLR4-MD-2 (58). E5531 also blocked endotoxin
response in human healthy volunteers challenged intravenously
with LPS (59). E5531 development went through phase 2 clinical
trial, but was stopped due to issues of bioavailability.
A second-generation LPS antagonist drug candidate developed
by Eisai is eritoran tetrasodium (known as eritoran or E5564), a
synthetic lipid A analog of Rhodobacter sphaeroides (60). Eritoran
blocked LPS-induced cytokines in vitro and in experimental ani-
mal models (61–63). In a phase 1 clinical trial enrolling healthy vol-
unteers challenged with LPS, eritoran inhibited pro-inflammatory
cytokine production and diminished clinical symptoms of sepsis,
including fever, chills, tachycardia, and headache. Additionally, C-
reactive protein levels and white blood counts were significantly
decreased (64–67). The only adverse event observed was a dose-
dependent phlebitis, due to the fact that high doses of eritoran
were used to achieve stable activity of the drug over time.
A phase 2 randomized control trial recruiting critically ill sep-
tic patients as assessed by the Acute Physiology and Chronic
Health Evaluation II (APACHE II) score disclosed a trend toward
decreased mortality in the eritoran treated group (37). Phase 3
ACCESS (A Controlled Comparison of Eritoran and placebo in
patients with Severe Sepsis) clinical trial for severe sepsis started
in 2006, and results were published in 2013. About 1304 patients
were treated with eritoran and 657 patients with placebo within
12 h after the onset of the first organ dysfunction. Unfortunately,
analyses did not reveal reduced all-cause mortality in primary and
secondary end-points (i.e., 28 days and 1 year mortality) (38). Eisai
(Tokyo, Japan) waived to submit eritoran to marketing authoriza-
tion for the treatment of severe sepsis in January 2011, based on
preliminary results of the ACCESS trial.
Several reasons may account for the lack of efficacy of eritoran
(68–70). For instance, patients were not enrolled or monitored
based on the circulating levels of LPS,questioning about the appro-
priateness of inclusion criteria. It is also possible that eritoran
would be more efficient if administrated rapidly, before septic
shock is underway, pointing the early and aggressive sepsis man-
agement as a possible interfering factor. Other factors to take into
account include the heterogeneity of patients for genetic back-
ground, underlying diseases, inflammatory and immune status,
sepsis severity, infectious agent, and site of infection. As mentioned
earlier, intracellular LPS sensed in a TLR4-independent manner
sensitizes mice to endotoxic shock (30, 31). This non-canonical
LPS detection may have limited the efficacy of the anti-TLR4 strat-
egy. Moreover, upon infection, innate immune cells will likely
sense several MAMPs via several TLRs and non-TLR PRRs. For
example, Gram-negative bacteria express MAMPs that may trigger
redundant inflammatory pathways through TLR2 (lipopeptides),
TLR4 (LPS), TLR5 (flagellin), TLR7 (ssRNA), and TLR9 (bacter-
ial DNA). All these observations suggest that blocking one single
pathway may be insufficient to interfere with the deleterious cas-
cade of events observed in sepsis. The positive side of the ACCESS
trial failure was a rethink of the design of sepsis clinical trials
(68–70). Clearly, a drug like eritoran should be tested in selected
patients and treatment efficacy examined and adjusted according
to predefined appropriate biomarkers (such as LPS blood levels
and genetic polymorphisms affecting the TLR4 pathway). A rigor-
ous approach combining the power of “omics” technologies would
allow the selection of homogeneous cohorts and the follow-up of
the response to treatment, both of which are mandatory for the
successful development of anti-sepsis drugs.
TAK-242
Another anti-sepsis agent that exhibited promising therapeutic
properties is TAK-242 [Ethyl-(6R)-[N -(2-chloro-4-fluorophenyl)
sulfamoyl] or resatorvid] from Takeda Pharmaceutical Company
(Osaka, Japan). TAK-242 was originally characterized as a sup-
pressor of nitric oxide (NO) and cytokine production by LPS-
stimulated macrophages and during endotoxic shock in mice (71).
TAK-242 binds to cysteine 747 in the intracellular domain of
TLR4, thereby inhibiting both MyD88-dependent and MyD88-
independent pathways activated by LPS (72). When administered
in conscious guinea pigs following LPS challenge, TAK-242 sig-
nificantly improved septic shock symptoms, decreasing HMGB1
systemic levels, and increasing survival in a dose-dependent man-
ner (73). TAK-242 also increased survival rates from 17 to 50% and
improved organ dysfunction when co-administered with antibi-
otics in a mouse model of cecal ligation and puncture (CLP).
No effect on circulating bacterial counts was observed (74). A
double-blind, randomized, placebo-controlled trial was initiated
with TAK-242 (39). Inclusion criteria comprised symptoms of
severe sepsis accompanied with either shock and/or respiratory
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failure. The study was stopped prematurely due to failure to
achieve significant decrease of systemic cytokine levels at stage
1 of the analysis (39). A phase 3 clinical study was designed but
never launched based on business decision and not due to safety
or efficacy concerns.
TLR4 ANTAGONISTIC ANTIBODIES AND OTHER TLR4 TARGETING
STRATEGIES
Antibodies directed against TLR4 or the TLR4-MD-2 complex
have been generated and showed promising results in several
pre-clinical studies. We engineered a soluble chimeric protein
composed of the N-terminal and central domains of mouse TLR4
(amino acid 1–334) fused to the Fc domain of human IgG1 (75).
The chimeric molecule was used to generate high titer anti-mouse
TLR4 rabbit polyclonal antibodies. The anti-TLR4 antibodies
powerfully inhibited NF-κB and MAPK activation and cytokine
production by LPS-stimulated cells in vitro. The antibodies also
hampered cytokine production and protected mice from lethal
endotoxemia when administered both prophylactically and thera-
peutically 4 h after LPS. Prophylactic administration of anti-TLR4
antibodies blunted TNF production and strikingly increased sur-
vival in E. coli sepsis, from 0% in the control antibody group to
80% in the anti-TLR4 group. Even more impressive, anti-TLR4
therapy initiated as much as 13 h after the onset of infection in
a model of E. coli peritoneal infection improved survival from
30 to 75% (75). Our studies demonstrate that anti-TLR4 anti-
bodies are efficient as adjunctive therapy for E. coli sepsis, with a
window of clinical application comprising prophylactic and thera-
peutic intervention opportunities. Several anti-TLR4 monoclonal
antibodies have been produced. The group of Miyake (Univer-
sity of Tokyo, Japan) reported in 2000 the generation of MTS510,
the first rat monoclonal antibody specific of the mouse TLR4-
MD-2 complex (76). MTS510 was shown to inhibit LPS-induced
NF-κB activation and TNF production by macrophages. 5E3 is a
rat monoclonal antibody produced by NovImmune SA (Geneva,
Switzerland) that reacts with the TLR4-MD-2 complex (77). 5E3
inhibited LPS-induced cell activation, and protected mice from
lethal endotoxemia when injected up to 7 h after LPS challenge.
Moreover, administration of 5E3 at the time of surgery improved
the outcome of mice with colon ascendens stent peritonitis, a
model of polymicrobial abdominal sepsis. Finally, the rat mon-
oclonal antibody 1A6, that recognizes both mouse and human
TLR4-MD-2 complexes, conferred protection in a model of E. coli
sepsis, but not Salmonella enterica, sepsis (78).
Although some TLR4 inhibitors have entered clinical and
pre-clinical trials, others remain in the developmental stage.
LPS-Trap-Fc antibodies (comprising the extracellular domain
of mouse TLR4 fused with MD-2 and linked to human IgG
Fc) dose-dependently decreased IL-6 release by macrophages,
opsonized Gram-negative bacteria, and enhanced phagocytosis
and complement-mediated bacterial killing (79). Cell-penetrating
peptides comprising the translocating segment of Drosophila
antennapedia homeodomain fused with BB loop sequences of
TLR4 (i.e., TLR4-BB peptides) inhibited LPS-induced NF-κB and
MAPK activation and cytokine production (80, 81). Further stud-
ies will be required before advancing these products toward the
clinical level.
Altogether, the experimental data reported above provided
strong support for the concept of TLR4-targeted therapy for
Gram-negative sepsis. In the gloomy context following the with-
drawn of rhAPC and eritoran from the sepsis field, it is hopeful
that NI-0101 has entered clinical development. NI-0101 is an
anti-TLR4 monoclonal antibody produced by NovImmune able
to block TLR4 dimerization and TLR4-mediated signaling trig-
gered by LPS and endogenous and chemical ligands of TLR4. Data
from pre-clinical studies in models of arthritis, respiratory inflam-
mation, and organ injury have highlighted the potential favorable
action of this agent3. A phase 1 clinical study is currently recruit-
ing participants to evaluate drug safety and tolerance in healthy
volunteers before and after ex vivo and in vivo LPS challenge. Phar-
macokinetics and pharmacodynamics will also be assessed. Results
from these studies are eagerly awaited.
TARGETING TLR4 IN FUNGAL AND VIRAL INFECTION
Albeit less well characterized, TLR4 has been implicated in the
sensing of non-bacterial microorganisms such as viruses and
fungi. TLR4 recognizes O-linked mannan from Candida albicans,
and human studies have linked Asp229Gly TLR4 polymorphism
with susceptibility to bloodstream candidiasis and pulmonary
aspergillosis (82–84). In a model of disseminated infection with
C. albicans, C3H/HeJ TLR4-deficient mice exhibited a 10-fold
increased fungal load in the kidneys, which was associated with
reduced production of the chemokines KC and MIP-2 and an
impaired recruitment of neutrophils (85). Treatment with HTA
125, an anti-human TLR4 mouse monoclonal antibody (86),
interfered with neutrophil-mediated protection against C. albi-
cans invasion and cell injury in an in vitro epithelial model of oral
candidiasis (87) and inhibited TNF production by human PBMCs
stimulated with Aspergillus hyphae (88). It is still unclear whether
targeting TLR4 may be beneficial in the context of fungal infec-
tions. A more clear yet unexpected picture has arisen from viral
infection studies. Reactive oxygen species (ROS) produced by the
NADPH oxidase generates oxidized host phospholipids that stim-
ulate TLR4 and the production of cytokines involved in acute
lung injury (89). Using a mouse model of lethal infection with
influenza, the group of Stephanie Vogel (University of Maryland,
Baltimore, MA, USA) reported that eritoran significantly increases
survival in a dose-dependent manner even when administered
6 days after viral challenge. Lung pathology and clinical symptoms
were improved while viral titers and influenza-induced cytokine
gene expression in lung homogenates were decreased compared to
the placebo-treated group. These data suggest that the therapeutic
effect of eritoran in a more practical timing of severe sepsis treat-
ment remains substantial (90). They also suggest that, despite the
failure of eritoran in the ACCESS trial, new therapeutic potentials
might still emerge for this agent.
TOLL-LIKE RECEPTOR 2
Toll-like receptor 2 has been implicated in the recognition of
an amazingly broad spectrum of microbial ligands originating
from bacteria, fungi, viruses, and parasites (91). This property
3http://www.novimmune.com
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is at least partly due to the fact that TLR2 forms heterodimers
with TLR1, TLR6, and possibly TLR10 (9, 15, 92). The biologi-
cal relevance of TLR2 homodimers is controversial. Indeed, some
ligands have been reported to trigger cells through TLR2 indepen-
dently of TLR1 and TLR6. Yet, only TLR2/TLR1 and TLR2/TLR6
heterodimers have been successfully crystallized (93, 94). TLR2
represents an interesting target for numerous conditions, but clin-
ical development of TLR2-targeting drugs has been less extensive
than that of TLR4.
TLR2 ANTAGONISTIC ANTIBODIES
T2.5 is a TLR2 neutralizing mouse monoclonal antibody.
T2.5 blocked Pam3CSK4 lipopeptide (a TLR1/TLR2-ligand)-
stimulated NF-κB nuclear translocation and MAPK phospho-
rylation in vitro. In models of Pam3CSK4-induced toxic shock
and microbial challenge with a high inoculum of heat-inactivated
Bacillus subtilis, T2.5 prevented lethal shock-like syndrome and
increased survival when administered 1 h before or up to 3 h after
infection (95). Furthermore, T2.5 used in combination with the
1A6 anti-TLR4/MD-2 antibody and antimicrobial therapy pro-
tected mice from sepsis caused by S. enterica and E. coli (78).
Intracellular antibodies, i.e., intrabodies, have been designed to
block the intracellular translocation of TLRs from the endoplas-
matic reticulum to the cell surface.αT2ib is a functional anti-TLR2
scFv intrabody comprising the variable domains of the heavy and
light chains of T2.5 linked together by a synthetic (Gly4Ser)3 amino
acid sequence. αT2ib bound intracellularly to TLR2 and led to
retention and accumulation of TLR2 inside the endoplasmatic
reticulum. Adenovirus-mediated expression of αT2ib in RAW
264.7 macrophages and mouse bone marrow derived macrophages
inhibited TLR2 surface expression and TLR2-ligand-driven TNF
production (96). These data suggest for a therapeutic potential of
T2.5 or αT2ib in microbial infections.
Many studies have attempted to elucidate the pathogenesis of
acute kidney injury associated with sepsis, which involves mecha-
nisms similar to those occurring during ischemia/reperfusion (97).
DAMPs released during infection are detected through TLR2 by
immune cells recruited to the ischemic tissue and/or by cells of the
ischemic tissue itself, amplifying the inflammatory response and
inducing injury upon reperfusion (98, 99). Blocking TLR2 under
these conditions may be cytoprotective (18). OPN-305 is a human-
ized anti-TLR2 IgG4 monoclonal antibody [derived from OPN-
301 (98) developed by Opsona Therapeutics (Dublin, Ireland)].
OPN-305 reduced TLR2-driven pro-inflammatory cytokine pro-
duction through blocking of TLR2/1 and TLR2/6 mediated sig-
naling. In a porcine model of myocardial ischemia/reperfusion
injury, pretreatment with OPN-305 or administration of OPN-
305 1 h after ischemia was associated with a 50% decrease in
infarct size (100). Results from a first in human phase 1 trial
evaluating safety, tolerability, pharmacokinetics, and pharmaco-
dynamics of ascending doses of OPN-305 given intravenously in
healthy adult subjects have just been released (101). TLR2 occu-
pancy and inhibition of IL-6 secretion induced by heat-killed
Listeria monocytogenes were assessed in whole blood collected up
to 90 days after treatment with either the antibody or placebo.
OPN-305 was well tolerated, with no significant toxicity even at
the highest dose tested. Impressively, OPN-305 at doses of 0.5
and 10 mg/kg occupied 100% of TLR2 molecules expressed on
monocytes collected 14 and 90 days after challenge, respectively.
IL-6 release was inhibited in a parallel manner. These results
suggest that treatment with OPN-305 could provide short-term
protection against ischemia/reperfusion and be adjusted to con-
fer long-lasting blockage in the case of TLR2-mediated chronic
diseases (101). A phase 2 trial assessing safety, tolerability, and effi-
cacy of OPN-305 in kidney transplant patients has been initiated
(NCT01794663).
OTHER TLR2 TARGETING STRATEGIES
New techniques are continuously implemented to facilitate the
identification of therapeutic targets for adjunctive treatment in
sepsis. Immunoprecipitation with systematic evolution of ligands
by exponential enrichment (SELEX) was developed to screen and
identify high-affinity DNA and RNA molecules that bind to TLR2
and could be used to detect other molecules influencing TLR-
driven activity. A most promising candidate, AP-177, was shown
to interact with TLR2, thereby obstructing ligand binding to the
receptor and inhibiting TLR2-ligand-induced NF-κB activity and
IL-6 and IL-8 production in THP-1 and HEK 293 cells (102). Cell-
penetrating TLR2-BB peptides have been generated and shown
to interfere with TLR2-ligand-induced activation of NF-κB and
MAPK and cytokine production (80). Whether these compounds
will undergo clinical evaluation is unknown.
TOLL-LIKE RECEPTOR 3
Toll-like receptor 3 is an endosomal PRR that senses dsRNA typi-
cally produced during viral infection (103). Experimental models
comparing TLR3 wild-type and TLR3 knockout mice revealed
either a protective role (West Nile virus, encephalomyocarditis
virus, poliovirus, coxsackievirus, murine cytomegalovirus, herpes
simplex virus), a deleterious role (West Nile virus, influenza A
virus, phlebovirus), or no influence (lymphocytic choriomenin-
gitis virus, vesicular stomatitis virus, murine cytomegalovirus,
reovirus) of TLR3 on anti-viral responses (104). Therefore, TLR3
agonists and antagonists might be efficient adjunctive therapies
for viral infections depending on the context. In the follow-
ing sections, we describe the development of synthetic dsRNA
TLR3 agonists (See TLR3 Agonists) and of synthetic ssDNA TLR3
antagonists and anti-TLR3 neutralizing antibodies (See TLR3
Antagonists).
TLR3 AGONISTS
The dsRNA synthetic analog polyinosinic:polycytidylic acid
[poly(I:C)] is a potent immunostimulant. For clinical develop-
ment, poly(I:C) was stabilized with polylysine and carboxymethyl-
cellulose (Poly-ICLC) (Hiltonol, Oncovir, Washington, DC, USA)
and used to generate poly(I:C12U) (rintatolimod, tradename
Ampligen, Hemispherx Biopharma, Philadelphia, PA, USA) by
substituting an uridylic acid at a molar ratio of 12:1 in the synthesis
of the polycytidylic acid strand (105). Poly(I:C) and its deriva-
tives have been tested in several clinical trials as adjuvants for
vaccines (for both infectious diseases and cancer) and comple-
ment to HAART (highly active anti-retroviral therapy) in human
immunodeficiency virus (HIV) infected patients, topics that we
do not discuss here.
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Poly(I:C12U) is highly specific for TLR3 and, unlike its parental
molecule poly(I:C), does not require Melanoma Differentiation-
associated protein 5 (MDA5, a cytosolic PRR for viruses), for the
induction of the signaling cascade leading to type I IFN pro-
duction (106). Poly(I:C12U) has some anti-viral activity against
HIV, hepatitis B virus (HBV), coxsackie B3 virus, and several
flaviviruses. Results from animal models of lethal respiratory
viral infection by severe acute respiratory syndrome coronavirus
(SARS-coV) and Punta Toro virus highlighted the favorable
impact of intranasal treatment with poly(I:C) or poly(I:C12U) on
survival and viral loads in infected mice (107, 108). The mode of
action of poly(I:C) in the respiratory tract was linked to the induc-
tion of caspase-mediated apoptosis and ROS, which are involved
in the cleavage and shedding of soluble TNF receptor blocking
TNF bioactivity (109). Interestingly, poly(I:C) protected against
bacterial infections in the respiratory tract as well as in the central
nervous system (CNS). In a mouse model of Pseudomonas aerug-
inosa pneumonia secondary to CLP, intranasal administration of
poly(I:C) improved immune activation and lowered bacterial load
in the lungs compared to the untreated animals (110). Corrobo-
rating results showing enhanced phagocytosis and killing of E.
coli by microglial cells suggest that TLR3 activation is crucial for
the immune response of CNS against invading pathogens (111,
112). These data support the development of TLR3 agonists as
adjuvant therapies to prevent or reduce the severity of respira-
tory tract infections caused by viruses and possibly bacteria. In
connection with that particular field, a phase 1 safety, tolerabil-
ity, and pharmacokinetic trial of nasally applied poly-ICLC in
human volunteers is ongoing and will explore immune activation
markers. A phase 1/2 clinical trial is assessing the immunogenicity
and safety of FluMist®(Live attenuated influenza vaccine, Med-
Immune, Gaithersburg, MD, USA) intranasal influenza vaccine
administered with and without a poly(I:C12U).
TLR3 ANTAGONISTS
More recently, TLR3 antagonists have been developed taking into
consideration that TLR3 over-activation by viral dsRNA may
have detrimental consequences in some situations. Indeed, it has
been reported that administration of poly(I:C) in mice prior to
intratracheal challenge with S. pneumoniae impaired bacterial
clearance and increased mortality. Excessive production of type
I IFN was involved in this phenomenon (113). Single-stranded
DNA oligonucleotides (ssDNA ODNs) efficiently competed with
dsRNA for binding to TLR3, thus inhibiting cytokine production
and costimulatory molecule expression by epithelial cells, PBMCs,
and dendritic cells (114, 115). The efficacy of ssDNA ODNs
was demonstrated in cynomolgus macaques, where intranasal
injection of ssDNAs ODNs inhibited poly(I:C)-induced cytokine
production in nasal secretions (115).
In addition to microbial ligands, TLR3 senses DAMPs released
from injured tissue during inflammation, for example RNA from
necrotic cells, promoting an excessive inflammatory response.
Interestingly, administration of a TLR3 neutralizing antibody to
mice reduced cecal damage induced by gut ischemia and improved
survival of animals with polymicrobial sepsis when the antibody
was given 6 and 24 h after CLP surgery (116). Collectively, these
data demonstrate that TLR3 works as an endogenous sensor of
necrosis and a regulator of the immune response, pointing to
receptor modulation as a possible adjuvant therapy for sepsis.
Work remains to be done to clearly delineate the precise role of
TLR3 in viral and bacterial infections and to appraise the benefit
afforded by TLR3 agonistic or antagonistic strategies for infectious
diseases, especially septic shock.
TOLL-LIKE RECEPTOR 5
A single TLR5 agonist has had clinical development, namely
CBLB502. Flagellin is the only ligand of TLR5 described to date.
Detailed structural basis of flagellin recognition by TLR5 has
been obtained through crystallographic analyses, unraveling a
unique mode of interaction between the two molecules as depicted
from stoichiometry, ligand arrangement, and binding interfaces
(117). The role of structural constraints for induction of the
NF-κB signaling cascade downstream TLR5 was supported by
structure-guided mutagenesis and deletion analyses on CBLB502
(Entolimob), a therapeutic agent derivative of S. enterica fla-
gellin implemented by Cleveland Biolabs (Buffalo, NY, USA).
CBLB502 is currently tested in a phase 1 trial in late stage cancer
patients (NCT01527136). Several clinical trials have investigated
the safety and adjuvant efficacy of recombinant flagellin in a num-
ber of vaccine settings (against influenza virus, Helicobacter pylori,
Campylobacter, Yersinia pestis, West Nile virus, etc) (118).
CBLB502 plays a protective role against radiation-induced tis-
sue injury, probably by suppressing apoptosis, attenuating ROS
generation, and promoting tissue regeneration (119). These prop-
erties could explain the beneficial effect of this agonist in a murine
model of acute ischemic renal failure when administered 30 min
after reperfusion (120). Highlighting the favorable role of flagellin
against tissue damage, results from two mouse studies suggested
that protection and repair of the intestinal mucosa that serves as a
first line defense barrier is the key mode of action of flagellin. In the
first study, flagellin was shown to induce the expression of RegIIIγ,
a C-type lectin with bactericidal activity, and to restrict small intes-
tine colonization with vancomycin-resistant Enterococcus (VRE)
in animals inoculated with VRE via oral gavage (121). In the sec-
ond study, treatment with flagellin reduced intestinal epithelium
destruction induced by dextran sodium sulfate (a chemical used to
induce severe acute colitis) and increased survival of mice inocu-
lated with S. typhimurium by oral gavage (122). These data suggest
that flagellin or TLR5 agonists may represent attractive tools for
treating pathologies that injure the intestinal tract, including severe
sepsis. No TLR5 antagonists have been reported.
TOLL-LIKE RECEPTOR 9
TLR9 AGONISTS
Toll-like receptor 9 agonists tested in clinical trials are syn-
thetic CpG oligodeoxynucleotides (CpG ODNs) among which
CPG10101, IMO-2125, SD-101, and CpG 7909 that mimic
unmethylated CpG dinucleotide-rich sequences enriched in
microbial DNA. CpG ODNs are powerful immunostimulants,
exploited for their adjuvant properties in vaccines against
infectious diseases (flu, malaria, HIV infection, pneumococcal
and meningococcal diseases) and cancer (melanoma, leukemia,
glioblastoma, and colorectal, prostate and breast cancer) (123).
The adjuvant properties of CpG ODNs have been used to enhance
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the phagocytosis and the killing of bacteria (S. typhimurium and S.
pneumoniae) by phagocytic cells (124, 125). Interestingly, a recent
study showed that CpG ODN given 1 h prior to CLP surgery pre-
vented CLP-induced cardiac dysfunction in mice. The authors
proposed that targeting TLR9 could be a useful approach for
the management of cardiovascular dysfunction in severe sepsis
patients (126).
Therapeutic strategies focusing on TLR9-mediated immuno-
modulation are currently being implemented for chronic viral
infections, such as chronic hepatitis C (HCV). Plasmacytoid den-
dritic cells are the main cells producing type I IFN and are therefore
considered to play an important role in viral infections. TLR9
agonists stimulate plasmacytoid dendritic cells to produce large
amounts of type I IFN, especially IFNα, which is the backbone of
therapy for HCV. Indeed, IFNα powerfully inhibits viral replica-
tion and promotes innate and adaptive host immune responses.
Moreover, IFN production appears to be impaired in plasmacytoid
dendritic cells of HCV patients (127, 128).
CPG10101 was originally developed under the trade name
Actilon by Coley Pharmaceuticals (Wellesley, MA, USA), a com-
pany recently incorporated by Pfizer (New York City, NY, USA).
CPG10101 has undergone two phase 1 studies with promising
results. A phase 1a study for drug safety and pharmacokinet-
ics conducted in 48 healthy volunteers revealed well tolerated
immunostimulatory effects without serious adverse events even
when using high doses of CPG10101 (129). CPG10101 was also
tested in 60 HCV patients, 50 infected with genotype 1 HCV.
CPG10101 was administered subcutaneously to four randomized
groups at different doses twice per week for 4 weeks alone or in
combination with pegylated IFNα and ribavirin. The TLR9 ago-
nistic effect of CPG10101 was associated with the induction of
IFNγ and IFNα and the decrease of viral loads. The only serious
adverse events were urticaria and pruritis, without manifestation
of respiratory complications (130). A phase 2 study enrolling 113
non-responders genotype 1 HCV patients has been completed, but
results have not been released yet.
IMO-2125, manufactured by Idera Pharmaceuticals (Cam-
bridge, MA, USA), has undergone two phase 1 trials: one for
dose estimation and one for safety, pharmacokinetics, and phar-
macodynamics, enrolling 60 and 40 treatment-naïve genotype
1 HCV patients, respectively. IMO-2125 administration dose-
dependently decreased viral loads, increased the production of
anti-viral cytokines and chemokines especially IFNα, and activated
NK and T-cell responses (41, 42). A phase 2 trial was planned, but
in April 2011 the company postponed its initiation. The decision
was made based on histological data from a 26-week non-clinical
toxicology study of IMO-2125 in rodents and non-human pri-
mates4. Preliminary analyses suggested evidence of atypical lym-
phocytic proliferation, although no adverse events were reported
in humans. Thorough analysis results are pending.
A phase 1b study sponsored by Dynavax (Berkeley, CA, USA)
investigated the safety and efficacy of SD-101 in chronic HCV.
SD-101 was administered as monotherapy or in combination with
ribavirin to 34 chronically infected, treatment-naïve, genotype 1
4http://ir.iderapharma.com
HCV patients. Results released in 2010 indicated that SD-101 was
well tolerated and safe without any serious adverse events. The
drug had significant anti-viral activity based on dose-dependent
anti-viral response, with 100% of patients at the highest dose
showing more than one log reduction in viral load, and increased
expression of type I IFN-dependent anti-viral genes (IP-10,MCP-1
MX-B, ISG-54K). These data comfort results from in vitro stud-
ies showing that SD-101 stimulated human PBMCs to produce
20-fold higher levels of both IFNα and IFNλ in comparison with
first-generation TLR9 agonists (40).
TLR9 ANTAGONISTS
Bacterial DNA released during infection is a MAMP, and exu-
berant activation of TLR9 may participate to the sepsis patho-
physiology. Hence, drug inhibitors of TLR9 may have therapeutic
potential in human sepsis. As a proof of concept, administration
up to 12 h after surgery of a single dose of an inhibitory CpG
ODN blocking TLR9 signaling protected mice from polymicrobial
sepsis following CLP (131). HMGB proteins are essential for trig-
gering nucleic acid receptor-mediated innate immune responses.
HMGB-binding non-immunogenic-ODNs have been designed to
inhibit HMGB-mediated pathologies. A non-immunogenic ODN
termed ISM ODN was tested in a mouse model of endotox-
emia. Impressively, 70% of mice treated with ISM ODN sur-
vived up to 72 h after LPS challenge, while all mice from the
control group died within 48 h (132). These data argue for a
possible use of non-immunogenic-ODNs in therapeutic inter-
ventions. Antimalarial drugs such as chloroquine are well known
for their anti-inflammatory properties in autoimmune diseases
such as rheumatoid arthritis and systemic lupus erythematosus
(133). Chloroquine blunted cytokine production and protected
mice from toxic shock induced by CpG ODN and LPS. Chloro-
quine down-regulated the expression of both TLR9 and TLR4,
suggesting that it acts at multiple levels to inhibit inflamma-
tion (134, 135). Additionally, when administered 6 h after CLP
in elderly mice treated with fluids and antimicrobials, chloroquine
significantly improved survival, strengthened renal function and
protected from multiple organ dysfunction (136). These results
support clinical evaluation of chloroquine in patients with severe
sepsis, especially those presenting with acute renal failure. Based
on its anti-inflammatory activity and because it inhibits endoso-
mal acidification which are important for cell infection by viruses,
chloroquine is also tested in multiple trials for prevention and/or
treatment of viral infections (HIV, influenza, dengue, chikun-
gunya). Yet, the mode of action of chloroquine is multi-factorial
and not only through TLR9.
TOLL-LIKE RECEPTOR 7 AND 8
Toll-like receptor 7 and 8 are closely related TLRs well known for
their capacity to recognize ssRNA from viruses such as HCV, HBV,
HIV, influenza virus, Herpes simplex virus, Epstein-Barr virus,
vesicular stomatitis virus, papilloma virus, respiratory syncytial
virus, and Sendai virus. In agreement, TLR7 is primarily expressed
in plasmacytoid dendritic cells. More recently, TLR7 and TLR8
were shown to sense bacterial RNA released within phagosomal
vacuoles (137). TLR7 and TLR8 triggering induces potent anti-
viral immune responses characterized by the production of type
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I IFNs and NF-κB-dependent cytokines. TLR7/8 agonists are pri-
marily developed for treating viral diseases, but also as adjuvants
for cancer and infectious disease vaccines.
TLR7/8 AGONISTS IN CHRONIC VIRAL INFECTIONS
Imiquimod (Aldara, originally developed by 3M Pharmaceuti-
cals, Maplewood, MN, USA) is the only TLR7 agonist marketed
for anti-viral treatment, i.e., external ano-genital warts caused
by human papilloma virus. Numerous TLR7/8 agonists are in
clinical development, like CL097, isatoribine, ANA975, ANA773,
PF-04878691 (852A), R-848 (resiquimod), and GS-9620.
Although therapeutic strategies for HCV have evolved in the
recent years, quest of new immunomodulatory targets remains
mandatory. Treatment with new agents such as protease inhibitors
appears to be efficient but presents with issues of resistance in
the long run (138). Moreover, current protocol therapy with IFNα
provides replenishment with a specific subtype of this cytokine.
However, use of TLR7 agonists is able to induce a variety of
IFN subtypes, possibly providing a more radical and integrated
anti-viral activity (139). Finally, administration of TLR7/8 ago-
nists may overcome the adverse events caused by IFNα, like the
suppression of granulocyte colony stimulating factor (G-CSF)
leading to neutropenia. Indeed, CL097 reversed IFNα-mediated
inhibition of G-CSF production by PBMCs obtained from HCV
patients and healthy volunteers (140). CL097 also restored defec-
tive cytokine production by myeloid dendritic cells from HIV
patients (141).
Isatoribine (Anadys Pharmaceuticals, San Diego, CA, USA)
was one of the first guanosin analog selective TLR7 agonists
to be implemented and tested on humans (142). Intravenous
administration of isatoribine to 12 HCV patients during a 7-
day treatment plan resulted in reduced plasma concentration
of HCV RNA, regardless virus genotype. Adverse events com-
prised dose-dependent joint pain, decreased white blood cells,
and platelets counts, insomnia, and headache (143). The develop-
ment of an oral prodrug that could lack the detrimental effects
of isatoribine, especially in the gastrointestinal tract, pointed
to a new candidate, ANA975. Preliminary results from a study
conducted with ANA975 were promising. Oral administration
of ANA975 presented with elevated plasma levels of isatoribine
at a concentration able to reduce HCV RNA in the plasma of
infected patients (144). Unfortunately, Anadys Pharmaceuticals
and Novartis (Basel, Switzerland) announced in 2007 discon-
tinuation of drug development due to unacceptable toxicity in
pre-clinical animal studies (145).
Subsequent elaboration of an oral prodrug of isatoribine
by Anadys Pharmaceuticals led to the generation of ANA773.
ANA773 exhibits efficient induction of endogenous type I IFNs.
A double-blind, placebo-controlled study was conducted in 34
patients with chronic HCV, either treatment-naïve or relapsed
from IFN-based therapy. Interestingly, ANA773 was safe and well
tolerated and presented only with grade 1 and 2 adverse events.
Moreover, ANA773 dose-dependently decreased HCV RNA lev-
els (48). In another study, repeated treatment with ANA773
was associated with transient decrease of myeloid and plasma-
cytoid dendritic cells and increased levels of IFNα and IP-10 in
the blood of patients achieving a reduction in the viral load,
suggesting an impairment in IFNα production in the case of
non-responders (49).
PF-04878691, formerly known as 852A, is a TLR7 agonist gen-
erated by Pfizer and implemented so that repeated low doses of
the drug would be accompanied with the benefits of the ago-
nistic activity without adverse events. A proof of concept study
was conducted to evaluate safety and tolerability of the drug and
to determine pharmacokinetics and pharmacodynamics. Twenty-
four healthy volunteers received orally increasing doses of PF-
04878691. PF-04878691 induced immune response in a dose-
dependent and frequency-related manner. However, two of the
subjects exhibited severe lymphopenia along with flu-like symp-
toms and hypotension (50). In an attempt to decide on the future
perspectives of this compound, a model was used to predict the
safety and efficacy of PF-04878691 in HCV patients. This model
exploited clinical results from the former study in healthy volun-
teers along with those reported from the use of CPG10101. Further
optimization will be required before entering the drug in a phase
2 study (146).
Other TLR7/8 agonists have reached phase 3 trials, but demon-
strated lack of efficacy and serious adverse effects. When mono-
cytes from HIV patients were stimulated with resiquimod, IL-12
secretion was augmented while TNF production was decreased
compared to the control group. Additionally, HIV replication
in cultured monocytes was inhibited (147). These promising
in vitro results were reproduced in a phase 2 trial that enrolled
patients with herpes simplex virus type 2. Topical application of
resiquimod protected from viral lesion spreading (148). However,
a phase 3 trial disclosed lack of efficacy of the drug and, although
a phase 2 study for the treatment of HCV demonstrated decreased
viral loads, adverse side effects similar to those resulting from IFNα
treatment were of serious concern (149).
Two phase 1 clinical trials for the safety and pharmacokinet-
ics of a novel compound, GS-9620 (Gilead Sciences, Foster City,
CA, USA), are currently enrolling treatment-naïve and viral sup-
pressed HBV patients respectively, while another one enrolling
HCV patients has been recently approved. GS-9620 is a TLR7 ago-
nist tested originally in HBV infected chimpanzees. Drug admin-
istration was associated with reduced viral loads both in plasma
and liver, probably through enhanced apoptosis of hepatocytes
(150). Testing of ascending dosages of the drug in healthy volun-
teers presented with flu-like adverse events at a dose of 8–12 mg,
but cytokine induction was achieved even at administration of
2 mg pointing to a promising adjunctive treatment for chronic
viral infections (151).
TLR7/8 AGONISTS IN ACUTE BACTERIAL AND VIRAL INFECTIONS
All the above data illustrate the efforts devoted to the develop-
ment of TLR7/8 agonists for treating viral pathologies. Taking
into account that bacterial RNA triggers TLR7 and TLR8 path-
ways, one may speculate that TLR7/8 agonists would impact on
bacterial sepsis. Unfortunately, there are almost no data available
on that subject. In one report, intravenous injection of R-848 prior
to sepsis induction using the colon ascendens stent peritonitis
model increased cytokine release and bacterial clearance, but the
effect on survival was not reported (152). Finally, considering that
excessive TLR activation induced by viruses or bacteria may have
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detrimental effects for the host, it might be of interest to gen-
erate TLR7/8 antagonists to counteract overwhelming immune
activation in conditions of severe infections.
CONCLUSION
Targeting TLRs is a promising field for sepsis management and
infection control. TLR agonists are widely used to optimize vaccine
efficacy, taking advantage of their powerful adjuvancity. Whether
TLR agonists and antagonists will have such success for treatment
therapies, especially for sepsis, has to be established. Agonists of
TLR3 and TLR7-9 yielded very promising results for treating viral
infections. Only few studies tested antagonistic drugs. Mainly for
historical reasons and because of their ligand specificity, TLR4 and
to a lesser extent TLR2 are the favorite targets for developing anti-
sepsis drugs. This domain of research has monopolized important
resources, but unfortunately many drugs tested in animal mod-
els have not entered human studies. Those that proceeded, like
eritoran and TAK-242, did not achieve primary endpoint goal
and/or were accompanied with manifestation of adverse events.
Animal models provide invaluable information about the role of
TLRs and the mechanism underlying infection pathogenesis, but
lack complexity in terms of comorbidities and host response com-
pared to human disease (153). So, how to explore more efficiently
new treatment strategies? Improving the design of clinical studies
is mandatory. We should discriminate those patients that could
benefit from therapy based on their genotype (for example affect-
ing TLR pathways) and the expression of the targeted molecule,
and select homogeneous, well-described population bearing the
same underlying conditions and disease severity (68–70, 154). Ide-
ally, sepsis studies should use specific biomarkers to help patient
enrollment and weigh treatment efficacy in realistic conditions
(155). The failure of the recent trials in patients with severe sepsis
has taught us valuable lessons regarding patient selection, time of
intervention, and follow-up (68–70). Blocking one single media-
tor may also not be sufficient to interfere with sepsis. Developing
sepsis-specific TLR-targeted therapies for patients is a path strewn
with obstacles, but an exciting and promising area of research.
These studies offer new possibilities for prevention and interven-
tion in infectious diseases, but also for other conditions, such as
cancer, allergy, asthma and autoimmune diseases either directly or
through improvement of vaccines.
ACKNOWLEDGMENTS
We would like to thank all our collaborators that participated
in our studies. Thierry Roger is supported through grants
from the Swiss National Science Foundation (310000_114073,
310030_132744, 310030_138488, and 310030_146838), an inter-
disciplinary grant from the Faculty of Biology and Medicine of
the University of Lausanne (Switzerland) and the European Com-
munity’s Seventh Framework Programme (FP7-2007-2013) under
grant agreement n° HEALTH-F2-2010-260338 – ALLFUN. Athina
Savva is recipient of a grant from the Porphyrogenis Foundation.
The authors have no competing interest to declare.
REFERENCES
1. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence
and mortality of severe sepsis in the United States. Crit Care Med (2013)
41:1167–74. doi:10.1097/CCM.0b013e31827c09f8
2. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impair-
ment and functional disability among survivors of severe sepsis. JAMA (2010)
304:1787–94. doi:10.1001/jama.2010.1553
3. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al.
Surviving sepsis campaign: international guidelines for management of severe
sepsis and septic shock, 2012. Intensive Care Med (2013) 39:165–228. doi:10.
1007/s00134-012-2769-8
4. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al.
Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med (2012)
366:2055–64. doi:10.1056/NEJMoa1202290
5. Ciarlo E, Savva A, Roger T. Epigenetics in sepsis: targeting histone deacetylases.
Int J Antimicrob Agents (2013) 42(Suppl):S8–12. doi:10.1016/j.ijantimicag.
2013.04.004
6. Namas R, Zamora R, Namas R, An G, Doyle J, Dick TE, et al. Sepsis: something
old, something new, and a systems view. J Crit Care (2012) 27(314):e1–11.
doi:10.1016/j.jcrc.2011.05.025
7. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat
Rev Immunol (2008) 8:776–87. doi:10.1038/nri2402
8. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate
immune system. Science (2010) 327:291–5. doi:10.1126/science.1183021
9. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate recep-
tors in infection and immunity. Immunity (2011) 34:637–50. doi:10.1016/j.
immuni.2011.05.006
10. Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and dis-
ease. Annu Rev Cell Dev Biol (2012) 28:137–61. doi:10.1146/annurev-cellbio-
101011-155745
11. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in
immunology. Cold Spring Harb Symp Quant Biol (1989) 54(Pt 1):1–13.
doi:10.1101/SQB.1989.054.01.003
12. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoven-
tral regulatory gene cassette spatzle/Toll/cactus controls the potent antifun-
gal response in Drosophila adults. Cell (1996) 86:973–83. doi:10.1016/S0092-
8674(00)80172-5
13. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS
signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science
(1998) 282:2085–8. doi:10.1126/science.282.5396.2085
14. Paul WE. Bridging innate and adaptive immunity. Cell (2011) 147:1212–5.
doi:10.1016/j.cell.2011.11.036
15. Broz P, Monack DM. Newly described pattern recognition receptors team
up against intracellular pathogens. Nat Rev Immunol (2013) 13:551–65.
doi:10.1038/nri3479
16. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR
signalling. Mediators Inflamm (2010) 2010:672395. doi:10.1155/2010/672395
17. Netea MG, van der Graaf C, Van der Meer JW, Kullberg BJ. Toll-like recep-
tors and the host defense against microbial pathogens: bringing specificity to
the innate-immune system. J Leukoc Biol (2004) 75:749–55. doi:10.1189/jlb.
1103543
18. Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning
CJ, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the
kidney. J Clin Invest (2005) 115:2894–903. doi:10.1172/JCI22832
19. O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adap-
tors in Toll-like receptor signalling. Nat Rev Immunol (2007) 7:353–64.
doi:10.1038/nri2079
20. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell
(2010) 140:805–20. doi:10.1016/j.cell.2010.01.022
21. Sato S, Nomura F, Kawai T, Takeuchi O, Muhlradt PF, Takeda K, et al. Synergy
and cross-tolerance between Toll-like receptor (TLR)2- and TLR4-mediated
signaling pathways. J Immunol (2000) 165:7096–101.
22. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected
Toll-like receptor agonist combinations synergistically trigger a T helper
type 1-polarizing program in dendritic cells. Nat Immunol (2005) 6:769–76.
doi:10.1038/ni1223
23. Dennehy KM, Ferwerda G, Faro-Trindade I, Pyz E, Willment JA, Taylor PR,
et al. Syk kinase is required for collaborative cytokine production induced
through dectin-1 and Toll-like receptors. Eur J Immunol (2008) 38:500–6.
doi:10.1002/eji.200737741
24. Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Wevers B, Bruijns SC,
et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical
Frontiers in Immunology | Microbial Immunology November 2013 | Volume 4 | Article 387 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Savva and Roger Targeting TLRs in infections
NF-kappaB activation through Raf-1 and Syk. Nat Immunol (2009) 10:203–13.
doi:10.1038/ni.1692
25. Franchi L, Amer A, Body-Malapel M, Kanneganti TD, Ozoren N, Jagirdar R,
et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin
1beta in salmonella-infected macrophages. Nat Immunol (2006) 7:576–82.
doi:10.1038/ni1346
26. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands
by NAIPs determines inflammasome specificity. Nature (2011) 477:592–5.
doi:10.1038/nature10394
27. Zhao Y, Yang J, Shi J, Gong YN, Lu Q, Xu H, et al. The NLRC4 inflammasome
receptors for bacterial flagellin and type III secretion apparatus. Nature (2011)
477:596–600. doi:10.1038/nature10510
28. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and mol-
ecular interactions of NOD1 and NOD2. Nat Rev Immunol (2006) 6:9–20.
doi:10.1038/nri1747
29. Landrigan A, Wong MT, Utz PJ. CpG and non-CpG oligodeoxynucleotides
directly costimulate mouse and human CD4+ T cells through a TLR9- and
MyD88-independent mechanism. J Immunol (2011) 187:3033–43. doi:10.
4049/jimmunol.1003414
30. Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA. Cytoplasmic LPS acti-
vates caspase-11: implications in TLR4-independent endotoxic shock. Science
(2013) 341:1250–3. doi:10.1126/science.1240988
31. Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura
S, et al. Noncanonical inflammasome activation by intracellular LPS indepen-
dent of TLR4. Science (2013) 341:1246–9. doi:10.1126/science.1240248
32. Carpenter S, O’Neill LA. How important are Toll-like receptors for antimi-
crobial responses? Cell Microbiol (2007) 9:1891–901. doi:10.1111/j.1462-5822.
2007.00965.x
33. Bochud PY, Bochud M, Telenti A, Calandra T. Innate immunogenetics: a tool
for exploring new frontiers of host defence. Lancet Infect Dis (2007) 7:531–42.
doi:10.1016/S1473-3099(07)70185-8
34. Chapman SJ, Hill AV. Human genetic susceptibility to infectious disease. Nat
Rev Genet (2012) 13:175–88. doi:10.1038/nrg3114
35. Netea MG, Wijmenga C, O’Neill LA. Genetic variation in Toll-like
receptors and disease susceptibility. Nat Immunol (2012) 13:535–42. doi:10.
1038/ni.2284
36. Hennessy EJ, Parker AE, O’Neill LA. Targeting Toll-like receptors: emerging
therapeutics? Nat Rev Drug Discov (2010) 9:293–307. doi:10.1038/nrd3203
37. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, et al. Phase 2
trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in
patients with severe sepsis. Crit Care Med (2010) 38:72–83. doi:10.1097/CCM.
0b013e3181b07b78
38. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al.
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients
with severe sepsis: the ACCESS randomized trial. JAMA (2013) 309:1154–62.
doi:10.1001/jama.2013.2194
39. Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, et al. A
randomized, double-blind, placebo-controlled trial of TAK-242 for the treat-
ment of severe sepsis. Crit Care Med (2010) 38:1685–94. doi:10.1097/CCM.
0b013e3181e7c5c9
40. Cianciara J, Martin JT, Spellman MC. Phase 1B dose-secalation study of SD-
101, a novel therapeutic TLR-9 agonist, in treatment-naive chronic hepatitis C
patients. In 45th Annual Meeting European Association for the Study of the Liver.
Vienna (2010).
41. Muir A, Ghalib R, Lawitz E, Patel K, Rodriguez-Torres M, Sheikh A, et al. A
phase 1, multi-center, randomized, placebo-controlled, dose-escalation study
of IMO-2125, a TLR9 agonist, in hepatitis C-nonresponders. In 45th Annual
Meeting European Association for the Study of the Liver. Vienna (2010).
42. Guyader D, Bogomolov P, Kobalava Z, Moiseev V, Szlavik J,Astruc B, et al. IMO-
2125 plus ribavirin gives substantial first-dose viral load reductions, cumulative
anti-viral effect, is well tolerated in naive genotype 1 HCV patients: a phase 1
trial. In 46th Annual Meeting European Association for the Study of the Liver.
Berlin (2011).
43. Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, et al. Chloroquine
for influenza prevention: a randomised, double-blind, placebo controlled trial.
Lancet Infect Dis (2011) 11:677–83. doi:10.1016/S1473-3099(11)70065-2
44. Borges MC, Castro LA, Fonseca BA. Chloroquine use improves dengue-related
symptoms. Mem Inst Oswaldo Cruz (2013) 108:596–9. doi:10.1590/S0074-
02762013000500010
45. Baker DA, Ferris DG, Martens MG, Fife KH, Tyring SK, Edwards L, et al.
Imiquimod 3.75% cream applied daily to treat anogenital warts: combined
results from women in two randomized, placebo-controlled studies. Infect Dis
Obstet Gynecol (2011) 2011:806105. doi:10.1155/2011/806105
46. Saiag P, Bauhofer A, Bouscarat F, Aquilina C, Ortonne JP, Dupin N, et al.
Imiquimod 5% cream for external genital or perianal warts in human immun-
odeficiency virus-positive patients treated with highly active antiretroviral ther-
apy: an open-label, noncomparative study. Br J Dermatol (2009) 161:904–9.
doi:10.1111/j.1365-2133.2009.09210.x
47. Miranda-Verastegui C, Tulliano G, Gyorkos TW, Calderon W, Rahme E, Ward
B, et al. First-line therapy for human cutaneous leishmaniasis in Peru using the
TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS
Negl Trop Dis (2009) 3:e491. doi:10.1371/journal.pntd.0000491
48. Bergmann JF, de Bruijne J, Hotho DM, de Knegt RJ, Boonstra A, Weegink CJ,
et al. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of
endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol
Ther (2011) 34:443–53. doi:10.1111/j.1365-2036.2011.04745.x
49. Boonstra A, Liu BS, Groothuismink ZM, Bergmann JF, de Bruijne J, Hotho DM,
et al. Potent immune activation in chronic hepatitis C patients upon admin-
istration of an oral inducer of endogenous interferons that acts via Toll-like
receptor 7. Antivir Ther (2012) 17:657–67. doi:10.3851/IMP2023
50. Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey
TP, et al. The innate immune response, clinical outcomes, and ex vivo HCV
antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther (2011)
89:821–9. doi:10.1038/clpt.2011.60
51. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of
endotoxin. Nat Rev Immunol (2003) 3:169–76. doi:10.1038/nri1004
52. Wittebole X, Castanares-Zapatero D, Laterre PF. Toll-like receptor 4 modu-
lation as a strategy to treat sepsis. Mediators Inflamm (2010) 2010:568396.
doi:10.1155/2010/568396
53. Wittebole X, Coyle SM, Kumar A, Goshima M, Lowry SF, Calvano SE. Expres-
sion of tumour necrosis factor receptor and Toll-like receptor 2 and 4 on
peripheral blood leucocytes of human volunteers after endotoxin challenge: a
comparison of flow cytometric light scatter and immunofluorescence gating.
Clin Exp Immunol (2005) 141:99–106. doi:10.1111/j.1365-2249.2005.02831.x
54. Harter L, Mica L, Stocker R, Trentz O, Keel M. Increased expression of Toll-
like receptor-2 and -4 on leukocytes from patients with sepsis. Shock (2004)
22:403–9. doi:10.1097/01.shk.0000142256.23382.5d
55. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis
of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature (2009)
458:1191–5. doi:10.1038/nature07830
56. Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, et al.
Bacterial endotoxin: molecular relationships of structure to activity and func-
tion. FASEB J (1994) 8:217–25.
57. Christ WJ, Asano O, Robidoux AL, Perez M, Wang Y, Dubuc GR, et al.
E5531, a pure endotoxin antagonist of high potency. Science (1995) 268:80–3.
doi:10.1126/science.7701344
58. Akashi S, Saitoh S, Wakabayashi Y, Kikuchi T, Takamura N, Nagai Y, et al.
Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2:
higher affinity than that with MD-2 or CD14. J Exp Med (2003) 198:1035–42.
doi:10.1084/jem.20031076
59. Bunnell E, Lynn M, Habet K, Neumann A, Perdomo CA, Friedhoff LT, et al.
A lipid A analog, E5531, blocks the endotoxin response in human volun-
teers with experimental endotoxemia. Crit Care Med (2000) 28:2713–20.
doi:10.1097/00003246-200008000-00005
60. Barochia A,Solomon S, Cui X, Natanson C, Eichacker PQ. Eritoran tetrasodium
(E5564) treatment for sepsis: review of preclinical and clinical studies. Expert
Opin Drug Metab Toxicol (2011) 7:479–94. doi:10.1517/17425255.2011.558190
61. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, et al.
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-
directed endotoxin antagonist. J Pharmacol Exp Ther (2003) 304:1093–102.
doi:10.1124/jpet.102.044487
62. Savov JD, Brass DM, Lawson BL, McElvania-Tekippe E, Walker JK, Schwartz
DA. Toll-like receptor 4 antagonist (E5564) prevents the chronic airway
response to inhaled lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol
(2005) 289:L329–37. doi:10.1152/ajplung.00014.2005
63. Zhou Z, Kozlowski J, Schuster DP. Physiologic, biochemical, and imaging char-
acterization of acute lung injury in mice. Am J Respir Crit Care Med (2005)
172:344–51. doi:10.1164/rccm.200503-343OC
www.frontiersin.org November 2013 | Volume 4 | Article 387 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Savva and Roger Targeting TLRs in infections
64. Liang E, Wong YN, Allen I, Kao R, Marino M, DiLea C. Pharmacokinet-
ics of E5564, a lipopolysaccharide antagonist, in patients with impaired
hepatic function. J Clin Pharmacol (2003) 43:1361–9. doi:10.1177/
0091270003258653
65. Lynn M, Wong YN, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, et al. Extended
in vivo pharmacodynamic activity of E5564 in normal volunteers with exper-
imental endotoxemia [corrected]. J Pharmacol Exp Ther (2004) 308:175–81.
doi:10.1124/jpet.103.056531
66. Rossignol DP, Wasan KM, Choo E, Yau E, Wong N, Rose J, et al. Safety, phar-
macokinetics, pharmacodynamics, and plasma lipoprotein distribution of eri-
toran (E5564) during continuous intravenous infusion into healthy volunteers.
Antimicrob Agents Chemother (2004) 48:3233–40. doi:10.1128/AAC.48.9.3233-
3240.2004
67. Rossignol DP, Wong N, Noveck R, Lynn M. Continuous pharmacodynamic
activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intra-
venous infusion into normal volunteers. Innate Immun (2008) 14:383–94.
doi:10.1177/1753425908099173
68. Cohen J, Opal S, Calandra T. Sepsis studies need new direction. Lancet Infect
Dis (2012) 12:503–5. doi:10.1016/S1473-3099(12)70136-6
69. Opal SM, LaRosa SP. Recombinant human activated protein C as a therapy for
severe sepsis: lessons learned? Am J Respir Crit Care Med (2013) 187:1041–3.
doi:10.1164/rccm.201303-0505ED
70. Tse MT. Trial watch: Sepsis study failure highlights need for trial design rethink.
Nat Rev Drug Discov (2013) 12:334. doi:10.1038/nrd4016
71. Yamada M, Ichikawa T, Ii M, Sunamoto M, Itoh K, Tamura N, et al. Dis-
covery of novel and potent small-molecule inhibitors of NO and cytokine
production as antisepsis agents: synthesis and biological activity of alkyl 6-
(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate. J Med Chem (2005)
48:7457–67. doi:10.1021/jm050623t
72. Takashima K, Matsunaga N, Yoshimatsu M, Hazeki K, Kaisho T, Uekata M,
et al. Analysis of binding site for the novel small-molecule TLR4 signal trans-
duction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model.
Br J Pharmacol (2009) 157:1250–62. doi:10.1111/j.1476-5381.2009.00297.x
73. Kuno M, Nemoto K, Ninomiya N, Inagaki E, Kubota M, Matsumoto T, et al.
The novel selective Toll-like receptor 4 signal transduction inhibitor tak-242
prevents endotoxaemia in conscious Guinea-pigs. Clin Exp Pharmacol Physiol
(2009) 36:589–93. doi:10.1111/j.1440-1681.2008.05121.x
74. Sha T, Iizawa Y, Ii M. Combination of imipenem and TAK-242, a Toll-
like receptor 4 signal transduction inhibitor, improves survival in a murine
model of polymicrobial sepsis. Shock (2011) 35:205–9. doi:10.1097/SHK.
0b013e3181f48942
75. Roger T, Froidevaux C, Le Roy D, Reymond MK, Chanson AL, Mauri D, et al.
Protection from lethal gram-negative bacterial sepsis by targeting Toll-like
receptor 4. Proc Natl Acad Sci U S A (2009) 106:2348–52. doi:10.1073/pnas.
0808146106
76. Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, et al. Cutting edge:
cell surface expression and lipopolysaccharide signaling via the Toll-like recep-
tor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol (2000)
164:3471–5.
77. Daubeuf B, Mathison J, Spiller S, Hugues S, Herren S, Ferlin W, et al. TLR4/MD-
2 monoclonal antibody therapy affords protection in experimental models of
septic shock. J Immunol (2007) 179:6107–14.
78. Spiller S, Elson G, Ferstl R, Dreher S, Mueller T, Freudenberg M, et al. TLR4-
induced IFN-gamma production increases TLR2 sensitivity and drives Gram-
negative sepsis in mice. J Exp Med (2008) 205:1747–54. doi:10.1084/jem.
20071990
79. Gross P, Brandl K, Dierkes C, Scholmerich J, Salzberger B, Gluck T, et al.
Lipopolysaccharide-trap-Fc, a multifunctional agent to battle gram-negative
bacteria. Infect Immun (2009) 77:2925–31. doi:10.1128/IAI.00004-09
80. Toshchakov VY, Fenton MJ, Vogel SN. Cutting edge: differential inhibition of
TLR signaling pathways by cell-permeable peptides representing BB loops of
TLRs. J Immunol (2007) 178:2655–60.
81. Toshchakov VY, Szmacinski H, Couture LA, Lakowicz JR, Vogel SN. Targeting
TLR4 signaling by TLR4 Toll/IL-1 receptor domain-derived decoy peptides:
identification of the TLR4 Toll/IL-1 receptor domain dimerization interface.
J Immunol (2011) 186:4819–27. doi:10.4049/jimmunol.1002424
82. Romani L. Immunity to fungal infections. Nat Rev Immunol (2011) 11:275–88.
doi:10.1038/nri2939
83. Cheng SC, Joosten LA, Kullberg BJ, Netea MG. Interplay between Candida albi-
cans and the mammalian innate host defense. Infect Immun (2012) 80:1304–13.
doi:10.1128/IAI.06146-11
84. Smeekens SP, van de Veerdonk FL, Kullberg BJ, Netea MG. Genetic suscepti-
bility to Candida infections. EMBO Mol Med (2013) 5:805–13. doi:10.1002/
emmm.201201678
85. Netea MG, Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW,
Kullberg BJ. The role of Toll-like receptor (TLR) 2 and TLR4 in the host
defense against disseminated candidiasis. J Infect Dis (2002) 185:1483–9.
doi:10.1086/340511
86. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, et al. MD-2, a
molecule that confers lipopolysaccharide responsiveness on Toll-like receptor
4. J Exp Med (1999) 189:1777–82. doi:10.1084/jem.189.11.1777
87. Weindl G, Naglik JR, Kaesler S, Biedermann T, Hube B, Korting HC, et al.
Human epithelial cells establish direct antifungal defense through TLR4-
mediated signaling. J Clin Invest (2007) 117:3664–72. doi:10.1172/JCI28115
88. Wang JE,Warris A, Ellingsen EA, Jorgensen PF, Flo TH, Espevik T, et al. Involve-
ment of CD14 and toll-like receptors in activation of human monocytes by
Aspergillus fumigatus hyphae. Infect Immun (2001) 69:2402–6. doi:10.1128/
IAI.69.4.2402-2406.2001
89. Imai Y, Kuba K, Neely GG,Yaghubian-Malhami R, Perkmann T, van Loo G, et al.
Identification of oxidative stress and Toll-like receptor 4 signaling as a key path-
way of acute lung injury. Cell (2008) 133:235–49. doi:10.1016/j.cell.2008.02.043
90. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, et al. The TLR4
antagonist eritoran protects mice from lethal influenza infection. Nature (2013)
497:498–502. doi:10.1038/nature12118
91. Oliveira-Nascimento L, Massari P, Wetzler LM. The role of TLR2 in infection
and immunity. Front Immunol (2012) 3:79. doi:10.3389/fimmu.2012.00079
92. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, et al. Human
TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic
cells, which activates gene transcription through MyD88. J Immunol (2005)
174:2942–50.
93. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, et al. Crystal structure of
the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide.
Cell (2007) 130:1071–82. doi:10.1016/j.cell.2007.09.008
94. Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S, et al. Recognition of lipopep-
tide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity
(2009) 31:873–84. doi:10.1016/j.immuni.2009.09.018
95. Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, et al.
Antagonistic antibody prevents Toll-like receptor 2-driven lethal shock-like
syndromes. J Clin Invest (2004) 113:1473–81. doi:10.1172/JCI200420762
96. Kirschning CJ, Dreher S, Maass B, Fichte S, Schade J, Koster M, et al. Genera-
tion of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2
expression and TLR2-driven cell activation. BMC Biotechnol (2010) 10:31.
doi:10.1186/1472-6750-10-31
97. Benes J, Chvojka J, Sykora R, Radej J, Krouzecky A, Novak I, et al. Searching for
mechanisms that matter in early septic acute kidney injury: an experimental
study. Crit Care (2011) 15:R256. doi:10.1186/cc10517
98. Arslan F, Smeets MB, O’Neill LA, Keogh B, McGuirk P, Timmers L, et al.
Myocardial ischemia/reperfusion injury is mediated by leukocytic Toll-
like receptor-2 and reduced by systemic administration of a novel anti-
Toll-like receptor-2 antibody. Circulation (2010) 121:80–90. doi:10.1161/
CIRCULATIONAHA.109.880187
99. Selejan S,Poss J,Walter F,Hohl M,Kaiser R,Kazakov A,et al. Ischaemia-induced
up-regulation of Toll-like receptor 2 in circulating monocytes in cardiogenic
shock. Eur Heart J (2012) 33:1085–94. doi:10.1093/eurheartj/ehr377
100. Arslan F, Houtgraaf JH, Keogh B, Kazemi K, de Jong R, McCormack WJ, et al.
Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody,
reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv
(2012) 5:279–87. doi:10.1161/CIRCINTERVENTIONS.111.967596
101. Reilly M, Miller RM, Thomson MH, Patris V, Ryle P, McLoughlin L, et al. Ran-
domized, double-blind, placebo-controlled, dose-escalating Phase I, healthy
subjects study of intravenous OPN-305, a humanized anti-TLR-2 antibody.
Clin Pharmacol Ther (2013) 94:593–600. doi:10.1038/clpt.2013.150
102. Chang YC, Kao WC, Wang WY, Wang WY, Yang RB, Peck K. Identifica-
tion and characterization of oligonucleotides that inhibit Toll-like receptor
2-associated immune responses. FASEB J (2009) 23:3078–88. doi:10.1096/fj.
09-129312
Frontiers in Immunology | Microbial Immunology November 2013 | Volume 4 | Article 387 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Savva and Roger Targeting TLRs in infections
103. Yu M, Levine SJ. Toll-like receptor, RIG-I-like receptors and the NLRP3 inflam-
masome: key modulators of innate immune responses to double-stranded RNA
viruses. Cytokine Growth Factor Rev (2011) 22:63–72. doi:10.1016/j.cytogfr.
2011.02.001
104. Matsumoto M, Oshiumi H, Seya T. Antiviral responses induced by the TLR3
pathway. Rev Med Virol (2011) 21:67–77. doi:10.1002/rmv.680
105. Carter WA, Pitha PM, Marshall LW, Tazawa I, Tazawa S, Ts’o PO. Structural
requirements of the rI n-rC n complex for induction of human interferon.
J Mol Biol (1972) 70:567–87. doi:10.1016/0022-2836(72)90560-8
106. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, et al. Essential
role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic
acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006)
103:8459–64. doi:10.1073/pnas.0603082103
107. Gowen BB, Wong MH, Jung KH, Sanders AB, Mitchell WM, Alexopoulou L,
et al. TLR3 is essential for the induction of protective immunity against Punta
Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U),
but not poly(I:C): differential recognition of synthetic dsRNA molecules.
J Immunol (2007) 178:5200–8.
108. Zhao J, Wohlford-Lenane C, Zhao J, Fleming E, Lane TE, McCray PB Jr, et al.
Intranasal treatment with poly(I*C) protects aged mice from lethal respiratory
virus infections. J Virol (2012) 86:11416–24. doi:10.1128/JVI.01410-12
109. Yu M, Lam J, Rada B, Leto TL, Levine SJ. Double-stranded RNA induces shed-
ding of the 34-kDa soluble TNFR1 from human airway epithelial cells via
TLR3-TRIF-RIP1-dependent signaling: roles for dual oxidase 2- and caspase-
dependent pathways. J Immunol (2011) 186:1180–8. doi:10.4049/jimmunol.
1001499
110. Davis CG, Chang K, Osborne D, Walton AH, Ghosh S, Dunne WM, et al. TLR3
agonist improves survival to secondary pneumonia in a double injury model.
J Surg Res (2013) 182:270–6. doi:10.1016/j.jss.2012.09.039
111. Ribes S, Adam N, Ebert S, Regen T, Bunkowski S, Hanisch UK, et al.
The viral TLR3 agonist poly(I:C) stimulates phagocytosis and intracellular
killing of Escherichia coli by microglial cells. Neurosci Lett (2010) 482:17–20.
doi:10.1016/j.neulet.2010.06.078
112. Town T, Jeng D, Alexopoulou L, Tan J, Flavell RA. Microglia recognize double-
stranded RNA via TLR3. J Immunol (2006) 176:3804–12.
113. Tian X, Xu F, Lung WY, Meyerson C, Ghaffari AA, Cheng G, et al. Poly I:C
enhances susceptibility to secondary pulmonary infections by gram-positive
bacteria. PLoS One (2012) 7:e41879. doi:10.1371/journal.pone.0041879
114. Ranjith-Kumar CT, Duffy KE, Jordan JL, Eaton-Bassiri A, Vaughan R, Hoose
SA, et al. Single-stranded oligonucleotides can inhibit cytokine production
induced by human Toll-like receptor 3. Mol Cell Biol (2008) 28:4507–19.
doi:10.1128/MCB.00308-08
115. Skold AE, Hasan M, Vargas L, Saidi H, Bosquet N, Le Grand R, et al. Single-
stranded DNA oligonucleotides inhibit TLR3-mediated responses in human
monocyte-derived dendritic cells and in vivo in cynomolgus macaques. Blood
(2012) 120:768–77. doi:10.1182/blood-2011-12-397778
116. Cavassani KA, Ishii M, Wen H, Schaller MA, Lincoln PM, Lukacs NW, et al.
TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory
events. J Exp Med (2008) 205:2609–21. doi:10.1084/jem.20081370
117. Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, et al.
Structural basis of TLR5-flagellin recognition and signaling. Science (2012)
335:859–64. doi:10.1126/science.1215584
118. Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential.
J Immunol (2010) 185:5677–82. doi:10.4049/jimmunol.1002156
119. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta
D, et al. An agonist of Toll-like receptor 5 has radioprotective activity in mouse
and primate models. Science (2008) 320:226–30. doi:10.1126/science.1154986
120. Fukuzawa N, Petro M, Baldwin WM III, Gudkov AV, Fairchild RLA. TLR5
agonist inhibits acute renal ischemic failure. J Immunol (2011) 187:3831–9.
doi:10.4049/jimmunol.1003238
121. Kinnebrew MA, Ubeda C, Zenewicz LA, Smith N, Flavell RA, Pamer EG.
Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against
vancomycin-resistant Enterococcus infection. J Infect Dis (2010) 201:534–43.
doi:10.1086/650203
122. Vijay-Kumar M, Aitken JD, Sanders CJ, Frias A, Sloane VM, Xu J, et al. Fla-
gellin treatment protects against chemicals, bacteria, viruses, and radiation.
J Immunol (2008) 180:8280–5.
123. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther
(2012) 22:77–89. doi:10.1089/nat.2012.0340
124. Lahiri A, Lahiri A, Das P, Vani J, Shaila MS, Chakravortty D. TLR 9 activa-
tion in dendritic cells enhances Salmonella killing and antigen presentation
via involvement of the reactive oxygen species. PLoS One (2010) 5:e13772.
doi:10.1371/journal.pone.0013772
125. Ribes S, Ebert S, Regen T, Agarwal A, Tauber SC, Czesnik D, et al. Toll-like
receptor stimulation enhances phagocytosis and intracellular killing of nonen-
capsulated and encapsulated Streptococcus pneumoniae by murine microglia.
Infect Immun (2010) 78:865–71. doi:10.1128/IAI.01110-09
126. Gao M, Ha T, Zhang X, Wang X, Liu L, Kalbfleisch J, et al. The Toll-like receptor
9 ligand, CpG oligodeoxynucleotide, attenuates cardiac dysfunction in polymi-
crobial sepsis, involving activation of both phosphoinositide 3 kinase/Akt and
extracellular-signal-related kinase signaling. J Infect Dis (2013) 207:1471–9.
doi:10.1093/infdis/jit036
127. Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, et al.
Rational design of new CpG oligonucleotides that combine B cell activation
with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol
(2003) 33:1633–41. doi:10.1002/eji.200323813
128. Libri NA, Barker SJ, Rosenberg WM, Semper AE. A class C CpG Toll-like
receptor 9 agonist successfully induces robust interferon-alpha production by
plasmacytoid dendritic cells from patients chronically infected with hepatitis
C. J Viral Hepat (2009) 16:315–24. doi:10.1111/j.1365-2893.2008.01011.x
129. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ,
Laframboise C, et al. Safety, pharmacokinetics and immune effects in normal
volunteers of CPG 10101 (ACTILON), an investigational synthetic Toll-like
receptor 9 agonist. Antivir Ther (2007) 12:741–51.
130. McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH,
et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101
in patients with chronic hepatitis C virus. Hepatology (2007) 46:1341–9.
doi:10.1002/hep.21773
131. Plitas G, Burt BM, Nguyen HM, Bamboat ZM, DeMatteo RP. Toll-like recep-
tor 9 inhibition reduces mortality in polymicrobial sepsis. J Exp Med (2008)
205:1277–83. doi:10.1084/jem.20080162
132. Yanai H, Chiba S, Ban T, Nakaima Y, Onoe T, Honda K, et al. Suppression
of immune responses by nonimmunogenic oligodeoxynucleotides with high
affinity for high-mobility group box proteins (HMGBs). Proc Natl Acad Sci U
S A (2011) 108:11542–7. doi:10.1073/pnas.1108535108
133. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism
of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.
J Immunol (2011) 186:4794–804. doi:10.4049/jimmunol.1000702
134. Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W. Chloroquine
inhibits proinflammatory cytokine release into human whole blood. Am J Phys-
iol (1998) 274:R1058–64.
135. Hong Z, Jiang Z, Liangxi W, Guofu D, Ping L, Yongling L, et al. Chloro-
quine protects mice from challenge with CpG ODN and LPS by decreasing
proinflammatory cytokine release. Int Immunopharmacol (2004) 4:223–34.
doi:10.1016/j.intimp.2003.12.006
136. Yasuda H, Leelahavanichkul A, Tsunoda S, Dear JW, Takahashi Y, Ito S,
et al. Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-
induced acute kidney injury. Am J Physiol Renal Physiol (2008) 294:F1050–8.
doi:10.1152/ajprenal.00461.2007
137. Sander LE, Davis MJ, Boekschoten MV, Amsen D, Dascher CC, Ryffel B, et al.
Detection of prokaryotic mRNA signifies microbial viability and promotes
immunity. Nature (2011) 474:385–9. doi:10.1038/nature10072
138. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW,
et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resis-
tant genotype 1 hepatitis C virus replication in patients. Hepatology (2007)
46:631–9. doi:10.1002/hep.21781
139. Megyeri K,Au WC, Rosztoczy I, Raj NB, Miller RL, Tomai MA, et al. Stimulation
of interferon and cytokine gene expression by imiquimod and stimulation by
Sendai virus utilize similar signal transduction pathways. Mol Cell Biol (1995)
15:2207–18.
140. Tajuddin T, Ryan EJ, Norris S, Hegarty JE, O’Farrelly C. Interferon-alpha
suppressed granulocyte colony stimulating factor production is reversed
by CL097, a TLR7/8 agonist. J Gastroenterol Hepatol (2010) 25:1883–90.
doi:10.1111/j.1440-1746.2010.06281.x
www.frontiersin.org November 2013 | Volume 4 | Article 387 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Savva and Roger Targeting TLRs in infections
141. Cardoso EC, Pereira NZ, Mitsunari GE, Oliveira LM, Ruocco RM, Francisco RP,
et al. TLR7/TLR8 activation restores defective cytokine secretion by myeloid
dendritic cells but not by plasmacytoid dendritic cells in HIV-infected preg-
nant women and newborns. PLoS One (2013) 8:e67036. doi:10.1371/journal.
pone.0067036
142. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular
basis for the immunostimulatory activity of guanine nucleoside analogs: acti-
vation of Toll-like receptor 7. Proc Natl Acad Sci U S A (2003) 100:6646–51.
doi:10.1073/pnas.0631696100
143. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, et al. Isatorib-
ine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis
C infection. Hepatology (2005) 42:724–31. doi:10.1002/hep.20839
144. Xiang AX, Webber SE, Kerr BM, Rueden EJ, Lennox JR, Haley GJ, et al. Discov-
ery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides
Nucleotides Nucleic Acids (2007) 26:635–40. doi:10.1080/15257770701490472
145. Fletcher S, Steffy K, Averett D. Masked oral prodrugs of Toll-like receptor 7
agonists: a new approach for the treatment of infectious disease. Curr Opin
Investig Drugs (2006) 7:702–8.
146. Jones HM, Chan PL, van der Graaf PH, Webster R. Use of modelling and
simulation techniques to support decision making on the progression of PF-
04878691, a TLR7 agonist being developed for hepatitis C. Br J Clin Pharmacol
(2012) 73:77–92. doi:10.1111/j.1365-2125.2011.04047.x
147. Nian H, Geng WQ, Cui HL, Bao MJ, Zhang ZN, Zhang M, et al. R-848 triggers
the expression of TLR7/8 and suppresses HIV replication in monocytes. BMC
Infect Dis (2012) 12:5. doi:10.1186/1471-2334-12-5
148. Mark KE, Corey L, Meng TC, Magaret AS, Huang ML, Selke S, et al. Top-
ical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital
shedding: a randomized, controlled trial. J Infect Dis (2007) 195:1324–31.
doi:10.1086/513276
149. Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, et al.
Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-
controlled, double-blind phase IIa studies. J Hepatol (2007) 47:174–82.
doi:10.1016/j.jhep.2007.02.025
150. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, et al.
GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppres-
sion of hepatitis B virus in chronically infected chimpanzees. Gastroenterology
(2013) 144:1508–17. doi:10.1053/j.gastro.2013.02.003
151. Lopatin U, Wolfgang G, Tumas D, Frey CR, Ohmstede C, Hesselgesser J, et al.
Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like
receptor 7 agonist. Antivir Ther (2013) 18:409–18. doi:10.3851/IMP2548
152. Koerner P, Traeger T, Mehmcke H, Cziupka K, Kessler W, Busemann A, et al.
Stimulation of TLR7 prior to polymicrobial sepsis improves the immune con-
trol of the inflammatory response in adult mice. Inflamm Res (2011) 60:271–9.
doi:10.1007/s00011-010-0265-6
153. Angus DC. The search for effective therapy for sepsis: back to the drawing
board? JAMA (2011) 306:2614–5. doi:10.1001/jama.2011.1853
154. Carlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis: time to recon-
sider the concept. Crit Care Med (2008) 36:964–6. doi:10.1097/CCM.
0B013E318165B886
155. Singer M. Biomarkers in sepsis. Curr Opin Pulm Med (2013) 19:305–9.
doi:10.1097/MCP.0b013e32835f1b49
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 25 September 2013; accepted: 05 November 2013; published online: 18
November 2013.
Citation: Savva A and Roger T (2013) Targeting Toll-like receptors: promising ther-
apeutic strategies for the management of sepsis-associated pathology and infectious
diseases. Front. Immunol. 4:387. doi: 10.3389/fimmu.2013.00387
This article was submitted to Microbial Immunology, a section of the journal Frontiers
in Immunology.
Copyright © 2013 Savva and Roger. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Immunology | Microbial Immunology November 2013 | Volume 4 | Article 387 | 16
